Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval

Executive Summary

Alexion plans to use voucher for one of its own products and might be targeting its next-generation version of blockbuster Soliris.


Related Content

Priority Review Vouchers Appear To Be Dropping In Price
No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company
Alexion Gets Second Priority Review Voucher With Approval Of Rare Enzyme Disorder Drug
Strensiq Average Annual Price Of $285,000 Has Room To Grow
Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval
Alexion Ultra-Rare Disease Candidate Makes “Breakthrough” List
Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts